Thomas Magg1, Anna Shcherbina2, Duran Arslan3, Mukesh M Desai4, Sarah Wall5, Vanessa Mitsialis6,7, Raffaele Conca1, Ekrem Unal8,9, Neslihan Karacabey3, Anna Mukhina2, Yulia Rodina2, Prasad D Taur4, David Illig1, Benjamin Marquardt1, Sebastian Hollizeck1, Tim Jeske1, Florian Gothe1, Tilmann Schober1, Meino Rohlfs1, Sibylle Koletzko1,10, Eberhard Lurz1, Aleixo M Muise11,12,13,10, Scott B Snapper5,6,7,10, Fabian Hauck1, Christoph Klein1,10, Daniel Kotlarz1,10. 1. Dr. von Hauner Children's Hospital, Department of Pediatrics, University Hospital, LMU Munich, Munich, Germany. 2. Institute of Hematology, Immunology and Cell Technologies, National Medical Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russian Federation. 3. Division of Pediatric Gastroenterology, Department of Pediatrics, Faculty of Medicine, Erciyes University, Melikgazi, Kayseri, Turkey. 4. Bai Jerbai Wadia Children Hospital, Mumbai, Parel, India. 5. Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, USA. 6. Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA. 7. Department of Medicine, Harvard Medical School, Boston, MA, USA. 8. Department of Pediatrics, Division of Pediatric Hematology & Oncology & HSCT Unit, Erciyes University, Melikgazi, Kayseri, Turkey. 9. Molecular Biology and Genetic Department, Gevher Nesibe Genom and Stem Cell Institution, Genome and Stem Cell Center (GENKOK), Erciyes University, Melikgazi, Kayseri, Turkey. 10. VEO-IBD Consortium, University Hospital, LMU Munich, Germany. 11. SickKids Inflammatory Bowel Disease Center and Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada. 12. Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada. 13. Department of Biochemistry University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Children with very early onset inflammatory bowel diseases (VEO-IBD) often have a refractory and severe disease course. A significant number of described VEO-IBD-causing monogenic disorders can be attributed to defects in immune-related genes. The diagnosis of the underlying primary immunodeficiency (PID) often has critical implications for the treatment of patients with IBD-like phenotypes. METHODS: To identify the molecular etiology in 5 patients from 3 unrelated kindred with IBD-like symptoms, we conducted whole exome sequencing. Immune workup confirmed an underlying PID. RESULTS: Whole exome sequencing revealed 3 novel CARMIL2 loss-of-function mutations in our patients. Immunophenotyping of peripheral blood mononuclear cells showed reduction of regulatory and effector memory T cells and impaired B cell class switching. The T cell proliferation and activation assays confirmed defective responses to CD28 costimulation, consistent with CARMIL2 deficiency. CONCLUSION: Our study highlights that human CARMIL2 deficiency can manifest with IBD-like symptoms. This example illustrates that early diagnosis of underlying PID is crucial for the treatment and prognosis of children with VEO-IBD.
BACKGROUND:Children with very early onset inflammatory bowel diseases (VEO-IBD) often have a refractory and severe disease course. A significant number of described VEO-IBD-causing monogenic disorders can be attributed to defects in immune-related genes. The diagnosis of the underlying primary immunodeficiency (PID) often has critical implications for the treatment of patients with IBD-like phenotypes. METHODS: To identify the molecular etiology in 5 patients from 3 unrelated kindred with IBD-like symptoms, we conducted whole exome sequencing. Immune workup confirmed an underlying PID. RESULTS: Whole exome sequencing revealed 3 novel CARMIL2 loss-of-function mutations in our patients. Immunophenotyping of peripheral blood mononuclear cells showed reduction of regulatory and effector memory T cells and impaired B cell class switching. The T cell proliferation and activation assays confirmed defective responses to CD28 costimulation, consistent with CARMIL2 deficiency. CONCLUSION: Our study highlights that humanCARMIL2 deficiency can manifest with IBD-like symptoms. This example illustrates that early diagnosis of underlying PID is crucial for the treatment and prognosis of children with VEO-IBD.
Authors: Anna S Lehle; Henner F Farin; Benjamin Marquardt; Birgitta E Michels; Thomas Magg; Yue Li; Yanshan Liu; Maryam Ghalandary; Katja Lammens; Sebastian Hollizeck; Meino Rohlfs; Fabian Hauck; Raffaele Conca; Christoph Walz; Batia Weiss; Atar Lev; Amos J Simon; Olaf Groß; Moritz M Gaidt; Veit Hornung; Hans Clevers; Nadine Yazbeck; Rima Hanna-Wakim; Dror S Shouval; Neil Warner; Raz Somech; Aleixo M Muise; Scott B Snapper; Philip Bufler; Sibylle Koletzko; Christoph Klein; Daniel Kotlarz Journal: Gastroenterology Date: 2018-09-26 Impact factor: 22.682
Authors: C L Bennett; J Christie; F Ramsdell; M E Brunkow; P J Ferguson; L Whitesell; T E Kelly; F T Saulsbury; P F Chance; H D Ochs Journal: Nat Genet Date: 2001-01 Impact factor: 38.330
Authors: Daniel Kotlarz; Rita Beier; Dhaarini Murugan; Jana Diestelhorst; Ole Jensen; Kaan Boztug; Dietmar Pfeifer; Hans Kreipe; Eva-Doreen Pfister; Ulrich Baumann; Jacek Puchalka; Jens Bohne; Odul Egritas; Buket Dalgic; Kaija-Leena Kolho; Axel Sauerbrey; Stephan Buderus; Tayfun Güngör; Axel Enninger; Yu Kar Ling Koda; Graziella Guariso; Batia Weiss; Selim Corbacioglu; Piotr Socha; Nuray Uslu; Ayse Metin; Ghassan T Wahbeh; Khalid Husain; Dina Ramadan; Waleed Al-Herz; Bodo Grimbacher; Martin Sauer; Karl-Walter Sykora; Sibylle Koletzko; Christoph Klein Journal: Gastroenterology Date: 2012-04-28 Impact factor: 22.682
Authors: Marc Edwards; Adam Zwolak; Dorothy A Schafer; David Sept; Roberto Dominguez; John A Cooper Journal: Nat Rev Mol Cell Biol Date: 2014-09-10 Impact factor: 94.444
Authors: Desirée Schubert; Claudia Bode; Rupert Kenefeck; Tie Zheng Hou; Lucy S K Walker; David M Sansom; Bodo Grimbacher; James B Wing; Alan Kennedy; Alla Bulashevska; Britt-Sabina Petersen; Alejandro A Schäffer; Björn A Grüning; Susanne Unger; Natalie Frede; Ulrich Baumann; Torsten Witte; Reinhold E Schmidt; Gregor Dueckers; Tim Niehues; Suranjith Seneviratne; Maria Kanariou; Carsten Speckmann; Stephan Ehl; Anne Rensing-Ehl; Klaus Warnatz; Mirzokhid Rakhmanov; Robert Thimme; Peter Hasselblatt; Florian Emmerich; Toni Cathomen; Rolf Backofen; Paul Fisch; Maximilian Seidl; Annette May; Annette Schmitt-Graeff; Shinji Ikemizu; Ulrich Salzer; Andre Franke; Shimon Sakaguchi Journal: Nat Med Date: 2014-10-20 Impact factor: 53.440
Authors: Aziz Bousfiha; Leïla Jeddane; Capucine Picard; Fatima Ailal; H Bobby Gaspar; Waleed Al-Herz; Talal Chatila; Yanick J Crow; Charlotte Cunningham-Rundles; Amos Etzioni; Jose Luis Franco; Steven M Holland; Christoph Klein; Tomohiro Morio; Hans D Ochs; Eric Oksenhendler; Jennifer Puck; Mimi L K Tang; Stuart G Tangye; Troy R Torgerson; Jean-Laurent Casanova; Kathleen E Sullivan Journal: J Clin Immunol Date: 2017-12-11 Impact factor: 8.317
Authors: Leila H Shayegan; Maria C Garzon; Kimberly D Morel; Rachel Borlack; Patricia M Vuguin; Kara G Margolis; Yesim Y Demirdag; Elaine M Pereira; Christine T Lauren Journal: Pediatr Dermatol Date: 2020-04-27 Impact factor: 1.588
Authors: O Toker; M Berger; O Shamriz; A J Simon; A Lev; O Megged; O Ledder; E Picard; L Joseph; V Molho-Pessach; Y Tal; P Millman; M Slae; R Somech Journal: Clin Exp Immunol Date: 2020-04-18 Impact factor: 4.330
Authors: Jennifer R Yonkof; Ajay Gupta; Cesar M Rueda; Shamlal Mangray; Benjamin T Prince; Hemalatha G Rangarajan; Mohammad Alshahrani; Elizabeth Varga; Timothy P Cripe; Roshini S Abraham Journal: Front Immunol Date: 2020-06-18 Impact factor: 7.561
Authors: Mara Cananzi; Aleixo M Muise; Luca Bosa; Vritika Batura; Davide Colavito; Karoline Fiedler; Paola Gaio; Conghui Guo; Qi Li; Antonio Marzollo; Claudia Mescoli; Ryusuke Nambu; Jie Pan; Giorgio Perilongo; Neil Warner; Shiqi Zhang; Daniel Kotlarz; Christoph Klein; Scott B Snapper; Thomas D Walters; Alberta Leon; Anne M Griffiths Journal: Sci Rep Date: 2021-03-15 Impact factor: 4.379